Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


Abstract Submission is Open

Submit your abstract

Abstract Submission Deadlines

All abstract submissions for an ESMO Virtual Plenary must be completed by 12:00hrs CET on the dates listed below:

Abstract submission deadline 

For ESMO Virtual Plenary presentation

Friday, 12 November 2021

Thursday, 16 December 2021

Friday, 10 December 2021

Thursday, 20 January 2022

Monday, 10 January 2022

Thursday, 10 February 2022

Friday, 11 February 2022

Thursday, 17 March 2022

Friday, 11 March 2022

Thursday, 21 April 2022

Friday, 8 April 2022

Thursday, 12 May 2022

Tuesday, 10 May 2022

Tuesday, 14 June 2022

Friday, 10 June 2022

Thursday, 14 July 2022

Friday, 16 September 2022

Thursday, 20 October 2022

Friday, 14 October 2022

Thursday, 17 November 2022

Friday, 11 November 2022

Wednesday, 14 December 2022

Eligibility for Submission

Abstracts containing original scientific data from randomized phase III trials in oncology, or from phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.

Real world data studies will be considered for eligibility based on scientific interest.

Submission Categories

  • Basic science
  • Biliary tract cancer, incl. cholangiocarcinoma
  • Biomarkers (agnostic)
  • Breast cancer, early stage
  • Breast cancer, locally advanced
  • Breast cancer, metastatic
  • CNS tumours
  • Colorectal cancer
  • Developmental therapeutics
  • Endocrine tumours
  • Genitourinary tumours, prostate
  • Genitourinary tumours, non-prostate
  • Gynaecological cancers
  • Haematological malignancies
  • Head and neck cancer, excluding thyroid
  • Hepatocellular carcinoma (HCC)
  • Investigational immunotherapy
  • Melanoma and other skin tumours
  • Miscellaneous
  • Neuroendocrine tumours
  • New diagnostic tools
  • NSCLC, early stage
  • NSCLC, locally advanced
  • NSCLC, metastatic
  • Oesophagogastric cancer
  • Palliative care
  • Pancreatic cancer
  • Psycho-oncology
  • Public policy
  • Sarcoma
  • SARS-CoV-2 and cancer
  • SCLC
  • Supportive care
  • Thoracic malignancies, other
  • Thyroid cancer
  • Translational research (agnostic)
  • Tumour biology and pathology

Review and Publication of Accepted Abstracts

Submitted abstracts will be reviewed by the the ESMO Virtual Plenary Review Panel comprising the ESMO President, ESMO President-elect, ESMO Chief Medical Officer, ESMO Congress Scientific Chairs and the appropriate Scientific Track Chairs.

Accepted abstracts will be granted an oral presentation by the first author, followed by expert perspectives and an interactive panel and audience discussion / Q&A session.

Presented abstracts will be published in Annals of Oncology as well as on the Annals of Oncology and ESMO websites.

Full abstract regulations are available here

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.